The Cost of 340B to State Employee Health Plans (White paper provided by IQVIA)
The Hidden Cost of 340B What Employers are Paying and What’s at Stake in Florida (February 5, 2026)
• Webinar Recording
Referenced resources:
• The 340B Program: Missing the mark for patients (2025 Johnson & Johnson Innovative Medicine Issue Brief)
• Calculation of Employers’ Lost Value due to 340B
The 340B drug program – accountability needed to protect patients, taxpayers
Op Ed by Karen van Caulil and Doug Wheeler, Director of the George Gibbs Center for Economic Prosperity at The James Madison Institute
PBM Reform and Health Policy: What It All Means for Employers (Policy Brief provided by the National Alliance, February 2026)
Employers Beware: Hidden Risks of 340B Shared Savings Models (Provided by the National Alliance, February 2026)
• Webinar Recording
• Slide deck
• Employers Beware: 340B Program Shared Savings Models Require Scrutiny (Action Brief)
With drug spending a top concern for plan sponsors and costs rising, employers continue to explore new strategies to better manage spending. New “shared savings” vendors attempt to appeal to employers frustrated with their traditional pharmacy benefit managers (PBMs). However, many rely on exploiting loopholes in the 340B Drug Pricing Program, which has been shown to drive up costs for employers. What they promise as short-term “savings” may in fact undermine continuity of care for employees and expose employers to reputational, regulatory, and even legal risks. This Action Brief provides employers with the tools to identify these vendors, understand the implications as plan sponsors, and consider alternatives to control health costs.
Flawed 340B Program Raises Costs for Employers and Working Families (resource provided by the National Alliance)
This one-pager highlights how the 340B drug pricing program, originally aimed at aiding safety-net providers, has evolved into a cost-driving tool for corporate healthcare. It reveals 340B’s growth into the second-largest federal drug program, often with limited benefits for the communities it was designed to support.
Relentless Health Value Podcast with Shawn Gremminger, President & CEO, National Alliance of Healthcare Purchaser Coalitions
• Part 1 – 340B: Where It Started, Where It Is Now, and Who Is Really Benefiting From This Massive Program
• Part 2 – 340B: Why Employers Should Probably Care About What’s Happening Here
The 340B Premium: New Data Shows Program Inflates Prices for Working Families (resource provided by the National Alliance)
A new analysis of commercial prices for high-volume procedures finds that hospital prices were 7% higher on average at large 340B hospitals compared with non-340B hospitals of similar size, equivalent to roughly $36 billion a year in additional spending by employers and working families. For outpatient procedures, the price premium at large 340B hospitals was even more significant, at nearly 20%.
New Study Reinforces Impact of 340B Drug Pricing Program on Rising Healthcare Costs for Employers – Roughly $36 Billion a Year in Extra Hospital Spending (Press Release, National Alliance, April 1, 2025)
Growth Unchecked: A Call to Action for Policymakers to Reform 340B, to Stop It from Driving Up Health Care Costs for Employers, Working Families and Taxpayers (Report by American Benefits Council, February 2025)